181261-73-4 Usage
General Description
4,5,6-Trichloronicotinic acid ethyl ester is a chemical compound with the formula C8H5Cl3NO2. It is an organic compound that is commonly used as a herbicide and pesticide due to its ability to inhibit the growth of plants and fungi. The ester form of trichloronicotinic acid allows for better solubility in organic solvents and enhanced stability, making it more effective for agricultural applications. However, it is important to handle this chemical with care, as it is toxic to humans and can cause irritation to the skin, eyes, and respiratory system. Additionally, it has the potential to be harmful to aquatic and terrestrial organisms, making it important to use this chemical responsibly to minimize environmental impact.
Check Digit Verification of cas no
The CAS Registry Mumber 181261-73-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,2,6 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 181261-73:
(8*1)+(7*8)+(6*1)+(5*2)+(4*6)+(3*1)+(2*7)+(1*3)=124
124 % 10 = 4
So 181261-73-4 is a valid CAS Registry Number.
181261-73-4Relevant articles and documents
Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1h)-ones
Wallace, Eli M.,Lyssikatos, Joseph,Blake, James F.,Seo, Jeongbeob,Yang, Hong Woon,Yeh, Tammie C.,Perrier, Michele,Jarski, Heidi,Marsh, Vivienne,Poch, Gregory,Livingston, Michelle Goyette,Otten, Jennifer,Hingorani, Gary,Woessner, Rich,Lee, Patrice,Winkler, James,Koch, Kevin
, p. 441 - 444 (2007/10/03)
The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.
